Exelixis, Inc. — Form 10-Q Summary
Period: Quarter ended March 31, 2017, compared with the three months ended March 31, 2016. The request metadata says “2016 Q1,” but the supplied filing is for 2017 Q1. The filing was signed May 1, 2017.
Business context
Exelixis is a biopharmaceutical company focused on cancer medicines. Its products include CABOMETYX and COMETRIQ, both based on cabozantinib, and COTELLIC, commercialized with Genentech. CABOMETYX’s U.S. launch for previously treated advanced kidney cancer began in April 2016. Exelixis also licenses cabozantinib internationally to Ipsen and, under a new agreement, to Takeda in Japan.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Total revenue | $80.9 million | $15.4 million |
| Net product revenue | $68.9 million | $9.1 million |
| Collaboration revenue | $12.0 million | $6.3 million |
| Operating income (loss) | $20.2 million | $(49.1) million |
| Net income (loss) | $16.7 million | $(59.2) million |
| Diluted earnings (loss) per share | $0.05 | $(0.26) |
| Operating cash flow | $68.9 million | $156.8 million |
- Revenue rose 424%, primarily reflecting CABOMETYX sales of $62.4 million; COMETRIQ revenue declined 28% to $6.5 million, partly as customers adopted CABOMETYX.
- Gross margin was 95%, compared with 92%, reflecting product mix; cost of goods sold was $3.2 million.
- Research and development expense was $23.2 million, down 20%; selling, general and administrative expense was $34.3 million, down 2%. The company expects R&D expense to increase as cabozantinib development advances.
- Cash and investments totaled $475.8 million at March 31, including $471.6 million available for operations and $4.2 million restricted long-term investments. Cash and cash equivalents alone were $183.2 million.
- Operating cash flow fell from $156.8 million, chiefly because Q1 2016 included Ipsen’s $200 million upfront payment. Q1 2017 included Takeda’s $50 million upfront payment, while product revenue also increased.
- Exelixis repaid its $80 million Silicon Valley Bank term loan in March. Remaining Deerfield Notes had $113.9 million principal outstanding and a 15% annual interest rate, half paid in kind. The company intended to repay them around July 1, 2017, at a premium; the notes were classified as current.
Material changes, outlook and risks
- Takeda paid a $50 million upfront fee for Japanese cabozantinib rights; Exelixis may receive up to $95 million in development, regulatory and first-sales milestones, up to $83 million in sales milestones, and tiered royalties.
- Exelixis and Bristol-Myers Squibb agreed to study cabozantinib with nivolumab, alone or with ipilimumab, including a planned Phase 3 first-line advanced kidney cancer trial. A separate collaboration with Roche will study cabozantinib with atezolizumab.
- Management planned to submit a supplemental application for first-line advanced kidney cancer in Q3 2017, based on CABOSUN results. The planned second interim analysis of the Phase 3 CELESTIAL liver cancer trial was expected in the second half of 2017. These are forward-looking plans, not reported outcomes.
- Management said current resources, product revenue and collaboration revenue were expected to fund operations for at least 12 months from the filing date, while warning that the planned Deerfield repayment would use a substantial portion of cash and could constrain operating plans. Exelixis cautioned that Q1 profitability may not continue; it had a $2.0 billion accumulated deficit.
- Key commercial risks include CABOMETYX adoption, reimbursement and drug-pricing pressure, competition, and dependence on Ipsen for international commercialization. Development and regulatory approvals for additional indications remain uncertain, and the company relies on third parties for manufacturing and clinical trials.
- Genentech withdrew its counterclaim in the COTELLIC arbitration and changed its allocation of U.S. promotional expenses, reducing Exelixis’s exposure to those costs. Other disputes over development, pricing, promotion and revenue allocation remained unresolved; the outcome and timing were uncertain.
- The filing disclosed an immaterial prior-period accounting error: Q1 2016 interest expense and net loss had each been overstated by $2.124 million, and loss per share by $0.01. The error did not affect cash flows or other reported totals. Management said it would correct affected prior periods prospectively in future filings.
Investor verification points
- Confirm the reporting period: this filing covers Q1 2017, despite the request metadata stating Q1 2016.
- Track CABOMETYX sales, discount and allowance reserves, reimbursement conditions, and COMETRIQ sales trends.
- Verify the timing, full cost and funding effect of the planned Deerfield Notes prepayment.
- Monitor CABOSUN regulatory progress, CELESTIAL trial updates, and the clinical and commercial progress of the Takeda, BMS, Ipsen and Roche collaborations.
- Follow the Genentech arbitration and confirm how its revised cost allocation affects Exelixis’s reported collaboration economics.
- Review subsequent filings for the disclosed accounting-error correction and any changes in liquidity or the company’s ability to sustain profitability.